Review of Vascular Access in Kidney Transplant Recipients: An Overlooked Topic. Experience of a Nontransplant Hospital
Transplantation Proceedings · 2026
DOI: 10.1016/j.transproceed.2026.01.001 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Transplantation Proceedings, 2026. Verfasst von Gabriel Ledesma und 11 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Department, Infanta Sofia University Hospital, Madrid, Spain; Faculty of Medicine, Health and Sports, Universidad Europea de Madrid, Madri…. Hauptthemen laut MEDLINE: Kidney Transplantation, Arteriovenous Shunt, Surgical, Renal Dialysis. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Vascular access management in kidney transplant recipients remains an underexplored topic, particularly in non-transplant hospitals. Arteriovenous fistulas (AVFs), commonly used during hemodialysis, may persist post-transplant and potentially affect cardiovascular health, especially when high-flow fistulas are present. OBJECTIVE: To evaluate the prevalence, status, and cardiovascular implications of AVFs in kidney transplant recipients under follow-up at a non-transplant center. METHODS: A cross-sectional, descriptive observational study was conducted at Infanta Sofía University Hospital, including 71 kidney transplant recipients. Data were collected on dialysis history and vascular access type. Doppler ultrasound was performed to assess flow and functionality of persistent AVFs. RESULTS: Of the 71 patients, 49% had a history of hemodialysis, with 77% of those having used AVFs. Among these, 78% of AVFs were no longer functional-mainly due to spontaneous thrombosis (57%) or surgical ligation (43%). The average time to ligation was 6 years post-transplant, with aneurysms being the leading indication. Only 6 functional AVFs remained, all native, with an average flow of 1634 mL/min. One patient with a Qa of 3000 mL/min was hospitalized for heart failure. Mild left ventricular hypertrophy was observed in 33% of patients with functional AVFs. CONCLUSION: Persistent AVFs are common in kidney transplant recipients and may pose a cardiovascular risk when high-flow is present. Despite the high rate of spontaneous or surgical closure, standardized follow-up and clear guidelines are lacking. Individualized decisions regarding AVF management should consider cardiovascular health, graft function, and future dialysis needs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Nephrology Department, Infanta Sofia University Hospital, Madrid, Spain; Faculty of Medicine, Health and Sports, Universidad Europea de Madrid, Madrid, Spain. Electronic address: gabriel.ledesma@salud.madrid.org.
- Nephrology Department, Infanta Sofia University Hospital, Madrid, Spain; Faculty of Medicine, Health and Sports, Universidad Europea de Madrid, Madrid, Spain.
- Nephrology Department, Infanta Sofia University Hospital, Madrid, Spain.
Zitieren
APA
Ledesma, G., Caldés, S., Hevia, C., Carreño, G., Mercado, V., Díaz, R., Echarri, R., Gallegos, A., Hernández, Y., Amezquita, Y., Bollain, C., & Cirugeda, A. (2026). Review of Vascular Access in Kidney Transplant Recipients: An Overlooked Topic. Experience of a Nontransplant Hospital. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2026.01.001
Vancouver
Ledesma G, Caldés S, Hevia C, Carreño G, Mercado V, Díaz R, et al. Review of Vascular Access in Kidney Transplant Recipients: An Overlooked Topic. Experience of a Nontransplant Hospital. Transplantation Proceedings. 2026. doi:10.1016/j.transproceed.2026.01.001
BibTeX
@article{Ledesma2026,
author = {Ledesma, Gabriel and Caldés, Silvia and Hevia, Covadonga and Carreño, Gilda and Mercado, Verónica and Díaz, Raquel and Echarri, Rocío and Gallegos, Angel and Hernández, Yolanda and Amezquita, Yesika and Bollain, Carmen and Cirugeda, Antonio},
title = {Review of Vascular Access in Kidney Transplant Recipients: An Overlooked Topic. Experience of a Nontransplant Hospital},
journal = {Transplantation Proceedings},
year = {2026},
doi = {10.1016/j.transproceed.2026.01.001}
}
EUVIMED